Exogenous mRNA transcripts often trigger TLR7/TLR8 immune pathways, leading to inflammation before transcription can occur. BioModifying’s chemical modification system incorporates pseudouridine variations that render the transcript invisible to innate cell defenses.
This allows for prolonged therapeutic translation cycles, extending the presence of therapeutic enzymes in the blood from 8 hours to 4.2 days post-infusion.